Drug delivery
Cure8 research brief
Why This Matters
Autoinjectors can make long-term biologic treatment easier, more convenient, and potentially improve adherence for people with Crohn’s disease or ulcerative colitis who use ustekinumab.
Demonstrating that patients, caregivers, and HCPs can safely use a disposable autoinjector matters for real-world treatment delivery and independence.
Who Should Pay Attention
Patients with Crohn’s disease or ulcerative colitis who use (or may use) ustekinumab, caregivers who administer injections, clinicians prescribing ustekinumab or biosimilars, and device regulators or manufacturers.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthFull source text
What To Know
The paper describes a nonclinical, simulated-use human factors validation study (not a clinical efficacy trial) assessing whether intended users can safely and effectively operate the Bmab 1200 autoinjector. Participants performed injections into foam pads without formal training while observers recorded use errors, task performance, and user confidence.
Results reported high usability: all participants completed injections, knowledge task success was very high (99.6%), and documented use errors were mostly related to hand hygiene, site prep, or device handling and did not cause device failure. Participants reported confidence and user-friendliness.
The device contains prefilled ustekinumab biosimilar syringes (45 mg or 90 mg) with a 29G needle and integrated needle shielding; the study aligns with regulatory human factors guidance and supports that the autoinjector is usable by intended users.
Keep In Mind
This was an in vitro simulated-use human factors validation study (not a clinical trial of drug efficacy or safety in patients). Injections were performed into foam pads rather than into people; reported outcomes concern device usability and user performance, not therapeutic effect.
The device contains a biosimilar ustekinumab formulation that has separate clinical comparability studies; this usability study supports device handling and self-administration.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationDrug delivery
AuthorsSam Moses K, Rohini Kamaraj, Suryaprakash Konda Ramachary Subramanian
InstitutionDevices R&D, Biocon Biologics Limited, Bengaluru, Karnataka, India.
Study typeJournal article, validation study
Indexed viaPubMed
Source typeResearch paper
PublishedMay 29, 2026, 12:00 AM
Content availableFull source text
Conflict statement: SMK, RK, and SKRS are employees of Biocon Biologics Limited. SMK and RK are eligible for stock and stock options, and SKRS holds stocks of Biocon.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
IBD colorectal guidelines
People with IBD have a higher lifetime risk of colorectal cancer; updated UK guidelines give clinicians and patients evidence-based recommendations on when and how to do surveillance colonoscopy to detect precancerous...
Crohn’s Disease vs. UC: Exploring Different Types of IBD
Understanding the differences between Crohn’s and ulcerative colitis helps patients and caregivers recognize likely symptom patterns, know which tests and treatments are commonly used, and when to seek specialist care....
Similarities and differences between Crohn's disease and ulcerative colitis
Patients with IBD or new symptoms should understand that Crohn’s disease and ulcerative colitis can look very similar but affect different parts of the gut and may require different treatments. Accurate diagnosis matters...